BioInvent International AB (LTS:0H22) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0H22 BioInvent International AB LTS:0H22
42 GF Score
Price kr23.40
GF Value kr50.31
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is BioInvent International AB Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

LTS:0H22
42GF Score
BioInvent International AB LTS:0H22
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioInvent International AB (LTS:0H22) Overvalued in 2026?

Based on GuruFocus' analysis, BioInvent International AB stock appears to be undervalued. The current stock price of kr23.40 is trading 53.5% below its estimated GF Value™ of kr50.31. GuruFocus considers BioInvent International AB to be Possible Value Trap.

Key valuation signals for LTS:0H22:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: kr50.31 vs. price of kr23.40 (53.5% below fair value)
  • GF Score™: 42/100 with 4 warning signs

No single metric tells the full story. See the LTS:0H22 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioInvent International AB Business Description

Other Exchanges BINV:SwedenBIX:Germany
Address Ideongatan 1, Lund, SWE, SE-223 70
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
42GF Score

Get the complete analysis for LTS:0H22

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr23.40
Price
kr50.31
GF Value